Gilead Sciences, Inc. (NASDAQ:GILD) Earns Hold Rating from BMO Capital Markets

BMO Capital Markets reissued their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report issued on Friday. BMO Capital Markets currently has a $72.00 price target on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. Zacks Investment Research raised Gilead Sciences from a strong sell rating to a hold rating in a research report on Tuesday, April 11th. William Blair reaffirmed an outperform rating on shares of Gilead Sciences in a research report on Friday, June 16th. Jefferies Group LLC reaffirmed a buy rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. Morgan Stanley reaffirmed an equal weight rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Finally, Credit Suisse Group reaffirmed an outperform rating and issued a $79.00 price objective on shares of Gilead Sciences in a research report on Friday, May 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $80.09.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 73.76 on Friday. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $88.85. The company’s 50 day moving average price is $68.32 and its 200-day moving average price is $68.63. The stock has a market capitalization of $96.38 billion, a P/E ratio of 7.80 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.66 billion. Equities analysts predict that Gilead Sciences will post $8.42 earnings per share for the current year.

WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Earns Hold Rating from BMO Capital Markets” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/07/24/gilead-sciences-inc-nasdaqgild-earns-hold-rating-from-bmo-capital-markets.html.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Stockholders of record on Friday, June 16th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Wednesday, June 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is 21.99%.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the sale, the director now owns 47,562 shares of the company’s stock, valued at $3,198,544.50. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock valued at $6,230,610 over the last 90 days. 1.30% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Norges Bank bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $997,048,000. Parnassus Investments CA raised its stake in Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the period. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the period. Numeric Investors LLC raised its stake in Gilead Sciences by 173.5% in the fourth quarter. Numeric Investors LLC now owns 2,820,505 shares of the biopharmaceutical company’s stock valued at $201,976,000 after buying an additional 1,789,101 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. raised its stake in Gilead Sciences by 75.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after buying an additional 1,092,206 shares during the period. Hedge funds and other institutional investors own 74.03% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published.

five × one =